Supplementary figure: Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Real-world weight changes in people with </b><b>HIV-1 at risk of weight gain (female, Black </b><b>or Hispanic) switching from integrase </b><b>strand transfer inhibitors</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Supplemental Figure 1: </b>Study design</li></ul><p dir="ltr"><b>Aim: </b>Compare weight changes between people living with HIV-1 (PLWH) at high risk of weight gain (females, Blacks or Hispanics) switching from an integrase strand transfer inhibitor (INSTI) to a protease inhibitor (PI) or another INSTI. <b>Materials & methods:</b> Mean weight changes from pre-switch to up-to-12 months post-switch were retrospectively compared between PLWH switching to a PI or INSTI. <b>Results: </b>356 PLWH were eligible. At 9- and 12-month post-switch, weight increases were observed for INSTI (weight: +1.55 kg and +1.59 kg), while decreases were observed for PI (-0.23 kg and -1.59 kg); differences between cohorts widened over time. Conclusion: These data suggest that switching off an INSTI may be a management tool to mitigate or reverse weight gain.</p>